Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 6c, beats revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $207.83 --0%
EPS Growth %: -22.5%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
EPS Growth %: -22.5%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.51, $0.06 better than the analyst estimate of $4.45. Revenue for the quarter came in at $957.32 million versus the consensus estimate of $941.99 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron beats estimates as refining margins lift earnings
- Regal-Beloit (RBC) Tops Q3 EPS by 21c ; Offers Guidance
- Jazz Pharmaceuticals (JAZZ) PT Raised to $300 at JPMorgan
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
